Psychedelics such as LSD and psilocybin have shown promise for treating alcohol use disorder by reducing drinking and promoting abstinence. Ayahuasca, an Amazonian brew containing β-carbolines and DMT, has also emerged as a potential treatment. Clinical studies, mostly retrospective, report significant decreases in alcohol use among ayahuasca users. Pre-clinical evidence indicates ayahuasca blocks abuse-related effects of alcohol. The chapter reviews clinical and pre-clinical evidence suggesting ayahuasca may be a promising new pharmacotherapy for alcohol use disorder and discusses potential mechanisms.
Male mice voluntarily drank ayahuasca over water when offered every other day, regardless of concentration. Extending the interval between exposures to every five days reversed this preference, producing aversion to ayahuasca, especially at higher concentrations. Frequency of exposure and concentration together influenced total ayahuasca intake during later re-exposure. These results indicate that both how often and how much ayahuasca is available determine preference in mice, which may inform therapeutic or ritualistic use.